{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:28:45Z","timestamp":1780489725254,"version":"3.54.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by the Sichuan Provincial Foundation of Science and Technology","award":["Grant Nos. 2023NSFSC0626"],"award-info":[{"award-number":["Grant Nos. 2023NSFSC0626"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This study aims to compare and analyze the effectiveness of different tumor regression grade (TRG) assessment systems in evaluating neoadjuvant therapy for esophageal cancer, with the goal of identifying an optimal assessment method to guide clinical practice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 467 patients with esophageal squamous cell carcinoma who underwent neoadjuvant therapy followed by surgical resection were included in this study. We comprehensively evaluated the effectiveness of five TRG assessment systems\u2014Mandard, CAP, Becker, JSED, and Ryan\u2014in predicting the prognosis of the primary tumor (PT) and lymph nodes (LN). The inter-observer consistency among these systems was also assessed to identify the most effective TRG evaluation method.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The performance of the TRG assessment systems in predicting LN prognosis was generally superior to that for PT. Specifically, while the Ryan criteria demonstrated the highest inter-observer consistency coefficient (Mean Kappa\u2009=\u20090.848), its predictive efficacy was the lowest (Mean AUC\u2009=\u20090.502). In contrast, the Becker criteria exhibited the highest predictive efficacy (Mean AUC\u2009=\u20090.609) alongside a good consistency coefficient (Mean Kappa\u2009=\u20090.788). Notably, the modified Modified TRG system not only achieved a higher AUC value (0.624) but also showed excellent inter-observer consistency (Kappa\u2009=\u20090.904).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The modified Modified TRG system, with a focus on LN evaluation, demonstrates superior prognostic predictive ability and risk stratification effectiveness. These findings may assist clinicians in more accurately assessing patient prognosis and adjusting treatment strategies accordingly, ultimately optimizing patient treatment pathways.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14726-4","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:21:37Z","timestamp":1755692497000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative analysis and optimization of tumor regression grade assessment systems in neoadjuvant therapy for esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Qiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingcheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengmin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"14726_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.humpath.2020.11.001","volume":"108","author":"G Saliba","year":"2020","unstructured":"Saliba G, Detlefsen S, Carneiro F, et al. Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an International Delphi consensus survey. HUM PATHOL. 2020;108:60\u20137. https:\/\/doi.org\/10.1016\/j.humpath.2020.11.001.","journal-title":"Hum Pathol"},{"issue":"34","key":"14726_CR2","doi-asserted-by":"publisher","first-page":"e1407","DOI":"10.1097\/MD.0000000000001407","volume":"94","author":"YK Chao","year":"2015","unstructured":"Chao YK, Chang CB, Chuang WY, et al. Correlation between tumor regression grade and clinicopathological parameters in patients with squamous cell carcinoma of the esophagus who received neoadjuvant chemoradiotherapy. Medicine. 2015;94(34):e1407. https:\/\/doi.org\/10.1097\/MD.0000000000001407.","journal-title":"Medicine"},{"key":"14726_CR3","doi-asserted-by":"crossref","unstructured":"Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer Am Cancer Soc. 1994;73(11):2680\u20136. https:\/\/pubmed.ncbi.nlm.nih.gov\/8194005\/.","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C"},{"issue":"8","key":"14726_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/DCR.0000000000000806","volume":"60","author":"T J\u00e4ger","year":"2017","unstructured":"J\u00e4ger T, Neureiter D, Urbas R, et al. Applicability of American joint committee on Cancer and college of American pathologists regression grading system in rectal Cancer. Dis Colon Rectum. 2017;60(8):815\u201326. https:\/\/doi.org\/10.1097\/DCR.0000000000000806.","journal-title":"Dis Colon Rectum"},{"issue":"7","key":"14726_CR5","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer Am Cancer Soc. 2003;98(7):1521\u201330. https:\/\/doi.org\/10.1002\/cncr.11660.","journal-title":"Cancer Am Cancer Soc"},{"key":"14726_CR6","doi-asserted-by":"crossref","unstructured":"Japan Esophageal Society. (2017) Japanese Classification of Esophageal Cancer, 11th Edition: part I. Esophagus 14:1\u201336.","DOI":"10.1007\/s10388-016-0551-7"},{"issue":"4","key":"14726_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1245\/s10434-019-07967-8","volume":"27","author":"FR Takeda","year":"2019","unstructured":"Takeda FR, Tustumi F, de Almeida Obregon C, et al. Prognostic value of tumor regression grade based on Ryan score in squamous cell carcinoma and adenocarcinoma of esophagus. Ann Surg Oncol. 2019;27(4):1241\u20137. https:\/\/doi.org\/10.1245\/s10434-019-07967-8.","journal-title":"Ann Surg Oncol"},{"key":"14726_CR8","doi-asserted-by":"publisher","first-page":"153538","DOI":"10.1016\/j.prp.2021.153538","volume":"224","author":"C L\u00fctken","year":"2021","unstructured":"L\u00fctken C, Sheikh K, Willemoe GL, et al. Clinical assessment of tumor regression grade systems in gastroesophageal adenocarcinoma following neoadjuvant chemotherapy. Pathol Res Pract. 2021;224:153538. https:\/\/doi.org\/10.1016\/j.prp.2021.153538.","journal-title":"Pathol Res Pract"},{"issue":"7","key":"14726_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S1470-2045(18)30201-8","volume":"19","author":"BJ Noordman","year":"2018","unstructured":"Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19(7):965\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(18)30201-8.","journal-title":"Lancet Oncol"},{"issue":"2","key":"14726_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.21037\/jgo.2018.12.01","volume":"10","author":"N Lerttanatum","year":"2019","unstructured":"Lerttanatum N, Tharavej C, Chongpison Y, et al. Comparison of tumor regression grading system in locally advanced esophageal squamous cell carcinoma after preoperative radio-chemotherapy to determine the most accurate system predicting prognosis. J Gastrointest Oncol. 2019;10(2):276\u201382. https:\/\/doi.org\/10.21037\/jgo.2018.12.01.","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"14726_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00428-017-2232-x","volume":"472","author":"R Langer","year":"2017","unstructured":"Langer R, Becker K. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Arch. 2017;472(2):175\u201386. https:\/\/doi.org\/10.1007\/s00428-017-2232-x.","journal-title":"Virchows Arch"},{"key":"14726_CR12","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fonc.2013.00262","volume":"3","author":"S Thies","year":"2013","unstructured":"Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. https:\/\/doi.org\/10.3389\/fonc.2013.00262.","journal-title":"Front Oncol"},{"issue":"7","key":"14726_CR13","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/cncr.10868","volume":"95","author":"MA Eloubeidi","year":"2002","unstructured":"Eloubeidi MA, Desmond R, Arguedas MR, et al. Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer Am Cancer Soc. 2002;95(7):1434\u201343. https:\/\/doi.org\/10.1002\/cncr.10868.","journal-title":"Cancer Am Cancer Soc"},{"issue":"19","key":"14726_CR14","doi-asserted-by":"publisher","first-page":"19633","DOI":"10.1002\/cam4.6597","volume":"12","author":"H Yin","year":"2023","unstructured":"Yin H, Yao Q, Xie Y, et al. Tumor regression grade combined with post-therapy lymph node status: a novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma. Cancer Med. 2023;12(19):19633\u201343. https:\/\/doi.org\/10.1002\/cam4.6597.","journal-title":"Cancer Med"},{"issue":"12","key":"14726_CR15","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.21873\/anticanres.12147","volume":"37","author":"K Mochizuki","year":"2017","unstructured":"Mochizuki K, Kondo T, Oishi N, et al. Esophagogastric junction carcinomas-discriminating histological types through immunohistochemistry. Anticancer Res. 2017;37(12):6855\u201361. https:\/\/doi.org\/10.21873\/anticanres.12147.","journal-title":"Anticancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14726-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T12:21:38Z","timestamp":1755692498000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14726-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14726"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14726-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee for Medical Research and New Medical Technology of Sichuan Cancer Hospital (Approval No. SCCHEC-02-2023-029) and conducted in accordance with the Declaration of Helsinki and relevant institutional\/national guidelines. As a retrospective analysis of anonymized historical patient data, the research did not involve direct patient interventions or modifications to clinical care. The ethics committee explicitly waived the requirement for informed consent due to the non-interventional nature of the study. All data were anonymized and handled in compliance with patient confidentiality standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1341"}}